Results 71 to 80 of about 79,216,419 (300)
OASIcs, Volume 75, ATMOS'19, Complete Volume
OASIcs, Volume 75, ATMOS'19, Complete ...
Cacchiani, Valentina +1 more
core +1 more source
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic +10 more
wiley +1 more source
LIPIcs, Volume 135, TQC'19, Complete Volume
LIPIcs, Volume 135, TQC'19, Complete ...
Mančinska, Laura, van Dam, Wim
core +1 more source
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani +9 more
wiley +1 more source
LIPIcs, Volume 139, CALCO'19, Complete Volume
LIPIcs, Volume 139, CALCO'19, Complete ...
Sokolova, Ana, Roggenbach, Markus
core +1 more source
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler +3 more
wiley +1 more source
LIPIcs, Volume 131, FSCD'19, Complete Volume
LIPIcs, Volume 131, FSCD'19, Complete ...
Geuvers, Herman
core +1 more source
Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim +11 more
wiley +1 more source
OASIcs, Volume 72, WCET'19, Complete Volume
OASIcs, Volume 72, WCET'19, Complete ...
Altmeyer, Sebastian
core +1 more source
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir +9 more
wiley +1 more source

